Results 51 to 60 of about 24,706 (195)
Juvenile idiopathic arthritis and malignancy [PDF]
Rheumatology, 2013 Biologic agents represent a major advance in the treatment of JIA. In 2008 a US Food and Drug Administration (FDA) warning raised the hypothesis that anti-TNF therapies may be associated with anincreased incidence of malignancies in children. More recent data seem to suggest that JIA itself, as in the case of RA, is associated with an increased risk of
Ruperto N, MARTINI, ALBERTO
openaire +4 more sources
Allergy, EarlyView.ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier +221 more
wiley +1 more source
Ovarian Reserve in Postpubertal Females with Juvenile Onset Idiopathic Arthritis [PDF]
Al-Azhar International Medical JournalBackground: Juvenile onset idiopathic arthritis is a chronic inflammatory disease that predominantly affects females in their early reproductive years, rendering the importance of considering ovarian reserve and future fertility, which may still be ...
Sherif Kandeel +2 more
doaj +1 more source
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis
Rheumatology, 2016 Systemic onset juvenile idiopathic arthritis (sJIA) is defined as arthritis affecting one or more joint usually in the juvenile age group (< 16 years of age) with or preceded by fever of at least 2 weeks duration that is documented to be daily ...
Deepak Jain +4 more
doaj +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Internal Medicine Journal, EarlyView.Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin‐6 (IL‐6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi‐organ failure.
Dipti Talaulikar +16 more
wiley +1 more source
Педиатрическая фармакология, 2007 Results of research of anti-inflammatory action and complications of preparations ibuprofen, nimesulid, diclofenac sodium are submitted at treatment of children and the adolescent suffered from juvenile idiopathic arthritis during the sharp period of ...
V.A. Kel’tsev, L.I. Grebenkina
doaj +2 more sources
Impact of socioeconomic status on disability in a longitudinal rheumatoid arthritis cohort
Internal Medicine Journal, EarlyView.Abstract The impact of socioeconomic status (SES) on health outcomes in Australians living with rheumatoid arthritis (RA) is not known. We aimed to determine whether differences in disability trajectory were present according to individuals' SES using longitudinal data from the Australian Rheumatology Association Database.
Oscar Russell +9 more
wiley +1 more source